John S. Driscoll earned a PhD in chemistry from Princeton University and after eight years as Research Group Leader in private industry, he joined the National Cancer Institute (NCI), National Institutes of Health, in Bethesda, MD where he initiated an intramural research program for the discovery of new anticancer drugs. From 1980 to 1983, he was Associate Director, Developmental Therapeutics Program for the NCI where he was responsible for managing preclinical intramural and extramural anticancer drug discovery and development. Dr Driscoll returned to experimental science as NCI's Chief of the Laboratory of Medicinal Chemistry. His laboratory conducted research in drug design, organic synthesis, analytical chemistry, biochemistry, pharmacology, and information technology in the area of new anticancer and anti-HIV drug discovery. He retired from the NCI after publishing over 140 scientific papers and obtaining numerous patents.